Skip to Main Content

Splitting Bluebird Bio into two publicly traded companies — one focused on cell therapies for cancer, the other on gene therapy for inherited diseases — is the best fix for the biotech’s recent struggles, CEO Nick Leschly told investors on Monday.

“Two birds are better than one,” said Leschly, speaking on a conference call in which he explained that dividing Bluebird into two companies “creates flexibility for each business,” “sharpens their focus,” and allows for “operational simplicity.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!